Argent Trust Co Has $5.39 Million Stake in Cencora, Inc. (NYSE:COR)

Argent Trust Co grew its position in Cencora, Inc. (NYSE:COR) by 1.9% during the 2nd quarter, Holdings Channel.com reports. The firm owned 23,903 shares of the company’s stock after purchasing an additional 449 shares during the period. Argent Trust Co’s holdings in Cencora were worth $5,385,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Rise Advisors LLC acquired a new stake in Cencora during the first quarter worth approximately $25,000. New Millennium Group LLC acquired a new stake in Cencora during the second quarter worth approximately $26,000. Legacy Bridge LLC acquired a new stake in Cencora during the first quarter worth approximately $27,000. TCTC Holdings LLC acquired a new stake in Cencora during the first quarter worth approximately $29,000. Finally, TFO Wealth Partners LLC acquired a new stake in Cencora during the first quarter worth approximately $30,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. StockNews.com raised Cencora from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Leerink Partners reissued an “outperform” rating and set a $275.00 price target on shares of Cencora in a research report on Thursday, June 27th. JPMorgan Chase & Co. increased their price target on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Wells Fargo & Company upped their target price on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 1st. Finally, Robert W. Baird cut their target price on Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a research note on Friday, September 6th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $258.13.

Cencora Stock Down 2.8 %

NYSE COR opened at $234.53 on Wednesday. Cencora, Inc. has a fifty-two week low of $177.00 and a fifty-two week high of $247.66. The stock has a market capitalization of $46.78 billion, a PE ratio of 25.66, a PEG ratio of 1.55 and a beta of 0.44. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. The business has a fifty day moving average price of $234.52 and a two-hundred day moving average price of $233.26.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The company had revenue of $74.20 billion during the quarter, compared to analysts’ expectations of $73.32 billion. During the same period in the prior year, the company earned $2.92 EPS. Cencora’s revenue was up 10.8% compared to the same quarter last year. Equities analysts expect that Cencora, Inc. will post 13.63 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were paid a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date was Friday, August 9th. Cencora’s payout ratio is 22.32%.

Insider Activity

In other news, CEO Steven H. Collis sold 10,755 shares of the stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the transaction, the chief executive officer now directly owns 285,088 shares in the company, valued at approximately $63,323,746.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Silvana Battaglia sold 1,473 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the transaction, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Steven H. Collis sold 10,755 shares of the firm’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total value of $2,388,900.60. Following the transaction, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at $63,323,746.56. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,450,399 shares of company stock worth $1,070,392,799. Insiders own 15.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.